Skip to main content
Home
About
Risks
News
Forums
Группы
Maps
Maps-new
Maps-old
Resources
Articles, Reports
Contacts
Links
Map Your Neighborhood
Resource Topics
Resource nodes
Systems
Dashboards
User login
Username
*
Password
*
Create new account
Request new password
lake
What is the weather on the sun
Search form
Поиск
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
US flu infections continue to climb, with more deaths among kids --CDC
Trump EPA Dismisses the Agency's Outside Science Advisers
Analysis: How the Secretary of Health and Human Services influences America's health efforts.
Map of bird flu infections in U.S. states
Americans' support for school vaccine mandates remains strong, but opt-out options gain traction --poll
Recent Comments
Nonprofit group says Trump's pause will be harmful to Americans
3 days 16 hours ago
The impact of Trump's move to quit WHO and on global health
1 week 3 days ago
Trump's Paris climate exit will hit harder than in 2017- experts
1 week 3 days ago
CDC warns of 'high' respiratory virus activity as cases increase
1 month 1 day ago
Who's online
There are currently 0 users online.
You are here
Главная страница
Merck's COVID treatment expected to launch in China on Friday
Primary tabs
View
(active tab)
Workflow
Wed, 2023-01-11 09:50 —
mike kraft
Merck's COVID treatment expected to launch in China on Friday
Merck & Co's COVID-19 antiviral treatment molnupiravir is expected to be launched in the Chinese market on Friday, Sinopharm's president Liu Yong was quoted as saying by state-backed media outlet Kankan News on Wednesday.
Reuters
Reuters
Country / Region Tags:
China
Global
United States
General Topic Tags:
COVID-19
Treatments
Disease
Health
Mutations
Pandemics
Public Health
Science
Problem, Solution, SitRep, or ?:
Situation Report
Groups this Group Post belongs to:
- Группа с ограниченным доступом -
Log in
or
register
to post comments
howdy folks
Page loaded in 0.459 seconds.
Recent Comments